Search Within

Natasha Morse

Formats
  1. Journal Article (6)
  2. Meeting Abstract (2)
Groups
  1. GSK Faculty (7)
  2. Sloan Kettering Institute Faculty (4)
  3. Sloan Kettering Institute Postdocs (4)
  4. Breast Medicine Service (3)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (3)
  6. Center for Pancreatic Cancer Research (3)

More Groups

People
  1. Jose Baselga (8)
  2. Maurizio Scaltriti (8)
  3. Ana Bosch Campos (3)
  4. Moshe Elkabets (3)
  5. Neal Rosen (3)
  6. Pau Castel (3)

More People

Years
  1. 2016 (2)
  2. 2015 (2)
  3. 2014 (2)
  4. 2013 (2)
Publications
  1. Science Translational Medicine (2)
  2. Cancer Cell (1)
  3. Cancer Research (1)
  4. Clinical Cancer Research (1)
  5. International Journal of Radiation Oncology, Biology, Physics (1)
  6. Proceedings of the National Academy of Sciences of the United States of America (1)

More Publications

Publishers
  1. American Association for the Advancement of Science (3)
  2. American Association for Cancer Research (2)
  3. Cell Press (1)
  4. Elsevier Inc. (1)
  5. National Academy of Sciences (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Taselisib (GDC-0032), a potent β-sparing small molecule inhibitor of PI3K, radiosensitizes head and neck squamous carcinomas containing activating PIK3CA alterations
    Journal Article

    Zumsteg, Z. S.; Morse, N.; Krigsfeld, G.; Gupta, G.; Higginson, D. S.; Lee, N. Y.; Morris, L.; Ganly, I.; Shiao, S. L.; Powell, S. N.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas
    Journal Article

    Ebbesen, S. H.; Scaltriti, M.; Bialucha, C. U.; Morse, N.; Kastenhuber, E. R.; Wen, H. Y.; Dow, L. E.; Baselga, J.; Lowe, S. W.
    Proceedings of the National Academy of Sciences of the United States of America (2016)

    Fulltext@MSK | Save
  • PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
    Journal Article

    Bosch, A.; Li, Z.; Bergamaschi, A.; Ellis, H.; Toska, E.; Prat, A.; Tao, J. J.; Spratt, D. E.; Viola-Villegas, N. T.; Castel, P.; more...
    Science Translational Medicine (2015)

    Fulltext@MSK | Save
  • AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
    Journal Article

    Elkabets, M.; Pazarentzos, E.; Juric, D.; Sheng, Q.; Pelossof, R. A.; Brook, S.; Benzaken, A. O.; Rodon, J.; Morse, N.; Yan, J. J.; more...
    Cancer Cell (2015)

    Fulltext@MSK | Save
  • GDC-0032, a novel p110 alpha inhibitor, specifically radiosensitizes head and neck squamous cell carcinomas harboring activating PIK3CA alterations
    Meeting Abstract

    Zumsteg, Z. S.; Morse, N.; Higginson, D.; Gupta, G.; Morris, L.; Ganly, I.; Grandis, J.; Lee, N. Y.; Powell, S. N.; Scaltriti, M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer
    Journal Article

    Tao, J. J.; Castel, P.; Radosevic-Robin, N.; Elkabets, M.; Auricchio, N.; Aceto, N.; Weitsman, G.; Barber, P.; Vojnovic, B.; Ellis, H.; more...
    Science Signaling (2014)

    Fulltext@MSK | Save
  • Combined blockade of PI3K/AKT and EGFR/HER3 enhances antitumor activity in triple negative breast cancer
    Meeting Abstract

    Scaltriti, M.; Tao, J.; Juric, D.; Auricchio, N.; Castel, P.; Morse, N.; Kim, P.; Singh, S.; Hazra, S.; Hembrough, T.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
    Journal Article

    Elkabets, M.; Vora, S.; Juric, D.; Morse, N.; Mino-Kenudson, M.; Muranen, T.; Tao, J.; Bosch Campos, A.; Rodon, J.; Ibrahim, Y. H.; more...
    Science Translational Medicine (2013)

    Fulltext@MSK | Save